

(11) **EP 3 572 093 A8**

(12) CORRECTED EUROPEAN PATENT APPLICATION

(15) Correction information:

Corrected version no 1 (W1 A1)

Corrections, see

Bibliography INID code(s) 72

(48) Corrigendum issued on:

15.01.2020 Bulletin 2020/03

(43) Date of publication:

27.11.2019 Bulletin 2019/48

(21) Application number: 19172994.6

(22) Date of filing: 31.03.2015

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated Extension States:

BA ME

Designated Validation States:

MA

(30) Priority: 31.03.2014 PCT/IB2014/000467

06.03.2015 PCT/IB2015/000288

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

15722580.6 / 3 125 936

(71) Applicant: Debiopharm International SA 1002 Lausanne (CH)

(72) Inventors:

TANAKA, Hiroaki
1004 Lausanne (CH)

(51) Int Cl.:

A61K 39/395 (2006.01)

C07K 14/435 (2006.01)

- MOULON, Corinne 1806 Saint-Léger (CH)
- VASLIN-CHESSEX, Anne 1008 Prilly (CH)
- WOJCIK, Jérôme 01220 Divonne-les-Bains (FR)
- ARMENISE, Claudia 01200 Eloise (FR)

(74) Representative: KATZAROV S.A.

European Patent Attorneys 12, Avenue des Morgines 1213 Petit-Lancy (CH)

Remarks:

- •This application was filed on 07-05-2019 as a divisional application to the application mentioned under INID code 62.
- •Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).

(54) FGFR FUSIONS

(57) The present invention relates to fusion polypeptides comprising an FGFR2 polypeptide and to cDNAs encoding such fusion polypeptides. The invention also encompasses methods of diagnosing the presence of

the fusion polypeptides or of a gene or RNA sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis.

EP 3 572 093 A8